We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Medtronic announced a series of worldwide clinical studies designed to further
demonstrate the patient and clinician advantages of the new implantable InSync
Sentry system to help detect and manage worsening heart failure.
Uroplasty, a medical device company that develops, manufactures and markets
a family of minimally invasive products used to treat urinary and fecal voiding
dysfunctions, announced that it has closed a financing transaction principally
with institutional investors generating gross proceeds to Uroplasty of $7.5
million.
Siemens Medical Solutions announced it has been awarded three-year contracts
with HealthTrust Purchasing Group (HPG) to provide its network of 1,500 participating
hospitals and healthcare systems access to Siemens magnetic resonance imaging
(MRI) and ultrasound technologies, effective through March 31, 2008.
Fresenius Medical Care, a provider of dialysis products and services, announced
that the products and hospital group (PHG) of its subsidiary Fresenius Medical
Care North America (FMCNA), headquartered in Lexington, Mass., acquired Haemotec,
a Quebec, Canada-based manufacturer of hemodialysis concentrates.
Digirad said that it asked for and received the resignation
of president and chief executive David Sheehan and fired another senior executive
after an internal investigation into accounting for the sale of a digital gamma
camera in 2004.
Cardima, developer of the INTELLITEMP and REVELATION series of cardiac interventional
systems for the treatment of atrial fibrillation (AF), received approval from
the regional ethic's committee at Guy's and St. Thomas Hospitals located in
London to conduct a clinical study using the REVELATION T-Flex and REVELATION
Helix catheters with the INTELLITEMP in the left atrium to create line of block
lesions for the treatment of AF.
Abiomed, a manufacturer of products for circulatory care and support, has announced
that the FDA will convene an expert panel of cardiovascular surgeons and cardiologists
to review the groundbreaking technologies and clinical trial data behind the
AbioCor artificial heart -- the first completely self-contained artificial heart
to come before the FDA for review.
Arbios Systems has received a conditional approval from the FDA for an investigational
device exemption (IDE) to begin a feasibility clinical trial for SEPET, Arbios'
extracorporeal (outside the body) artificial liver assist device for blood purification
for patients in acute liver failure.